| DIRECT COMPETITOR COMPARISON | |
| DUSA | Pvt1 | PCYC | QLTI | Industry | | Market Cap: | 32.55M | N/A | 111.66M | 258.40M | 176.84M | | Employees: | 85 | N/A | 46 | 135 | 94 | | Qtrly Rev Growth (yoy): | 21.00% | N/A | N/A | -19.20% | 22.40% | | Revenue (ttm): | 28.81M | N/A | N/A | 118.97M | 42.63M | | Gross Margin (ttm): | 75.19% | N/A | N/A | 33.84% | 55.30% | | EBITDA (ttm): | -4.68M | N/A | -19.73M | 21.60M | -7.66M | | Oper Margins (ttm): | -17.88% | N/A | N/A | 16.94% | 2.08% | | Net Income (ttm): | -4.87M | N/A | -21.75M | 22.11M | N/A | | EPS (ttm): | -0.202 | N/A | -0.717 | 0.403 | -0.17 | | P/E (ttm): | N/A | N/A | N/A | 11.74 | 17.43 | | PEG (5 yr expected): | N/A | N/A | N/A | N/A | 1.01 | | P/S (ttm): | 1.15 | N/A | N/A | 2.14 | 4.43 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.85 | 0.53% | 57.54B | 12.40 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 48.18 | 1.69% | 13.93B | 16.12 | | Genzyme Corp. | GENZ | 49.98 | -0.58% | 13.26B | 28.49 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.59 | 0.71% | 41.93B | 18.02 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 50.64 | 0.78% | 9.03B | 1033.47 | | Teva Pharmaceutical Industries Limited | TEVA | 54.01 | 0.82% | 47.58B | 49.41 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.90 | 1.64% | 4.02B | 19.54 | | King Pharmaceuticals Inc. | KG | 11.72 | 0.43% | 2.91B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 17.99 | -1.15% | 5.50B | 110.37 | | Pfizer Inc. | PFE | 18.49 | -0.80% | 149.21B | 15.36 | | Johnson & Johnson | JNJ | 64.36 | 0.31% | 177.58B | 14.06 | | GlaxoSmithKline plc | GSK | 42.75 | 0.73% | 108.37B | 13.49 | | Sanofi-Aventis | SNY | 39.38 | -0.35% | 102.83B | N/A | | Novartis AG | NVS | 55.55 | -0.41% | 126.17B | 16.63 |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | RHHBY.PK | 41.42 | -1.03% | N/A | N/A | | AstraZeneca plc | AZN | 46.30 | 1.49% | 67.13B | 9.30 | | Abbott Laboratories | ABT | 53.78 | -0.85% | 83.18B | 14.57 | | Bristol-Myers Squibb Co. | BMY | 25.14 | -0.08% | 49.80B | 13.01 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | PCYC | | Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting
Sun 7:00pm -
PR Newswire | | • | PCYC | | Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7
Thu, Dec 3 -
PR Newswire | | • | QLTI | | QLT INC/BC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Tue, Dec 1 -
EDGAR Online | | • | QLTI | | Picks of the Week: Microsoft, H-P, Goldman, TiVo
Mon, Nov 30 -
at BusinessWeek | | • | QLTI | | Before the Bell: Renault, Dubai, QLT in focus
Fri, Nov 27 -
at MarketWatch | | • | QLTI | | QLT Inc upgraded by RBC Capital Mkts
Fri, Nov 27 -
Briefing.com | | • | QLTI | | QLT INC/BC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Wed, Nov 25 -
EDGAR Online | | • | PCYC | | Still Believe in Antigenics
Tue, Nov 24 -
at Seeking Alpha | | • | PCYC | | PHARMACYCLICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Thu, Nov 12 -
EDGAR Online | | • | PCYC | | Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
Thu, Nov 12 -
PR Newswire | | • | PCYC | | Pharmacyclics to Present at Merriman Curhan Ford's Investor Summit 2009
Mon, Nov 9 -
PR Newswire | | | All Headlines for these symbols... |
|
|
|
0.22% Nasdaq 
0.02 (1.46%) 
Competitors
